Literature DB >> 32813049

A 5-year clinical follow-up study from the Italian National Registry for FSHD.

Liliana Vercelli1, Fabiano Mele2, Lucia Ruggiero3, Francesco Sera4, Silvia Tripodi5, Giulia Ricci2,6, Antonio Vallarola7,8, Luisa Villa9, Monica Govi2, Louise Maranda10, Antonio Di Muzio11, Marina Scarlato12, Elisabetta Bucci13, Lorenzo Maggi14, Carmelo Rodolico15, Maurizio Moggio9, Massimiliano Filosto16, Giovanni Antonini13, Stefano Previtali12, Corrado Angelini17, Angela Berardinelli18, Elena Pegoraro5, Gabriele Siciliano6, Giuliano Tomelleri7,8, Lucio Santoro3, Tiziana Mongini19, Rossella Tupler20,21,22,23.   

Abstract

BACKGROUND: The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined.
METHODS: An observational cohort study was conducted in 246 FSHD1 patients. We split the analysis between index cases and carrier relatives and we classified all patients using the Comprehensive Clinical Evaluation Form (CCEF). The disease progression was measured as a variation of the FSHD score performed at baseline and at the end of 5-year follow-up (ΔFSHD score).
FINDINGS: Disease worsened in 79.4% (112/141) of index cases versus 38.1% (40/105) of carrier relatives and advanced more rapidly in index cases (ΔFSHD score 2.3 versus 1.2). The 79.1% (38/48) of asymptomatic carriers remained asymptomatic. The highest ΔFSHD score (1.7) was found in subject with facial and scapular weakness at baseline (category A), whereas in subjects with incomplete phenotype (facial or scapular weakness, category B) had lower ΔFSHD score (0.6) p < 0.0001.
CONCLUSIONS: The progression of disease is different between index cases and carrier relatives and the assessment of the CCEF categories has strong prognostic effect in FSHD1 patients.

Entities:  

Keywords:  Clinical categories; D4Z4 reduced allele; FSHD; Follow-up

Mesh:

Year:  2020        PMID: 32813049      PMCID: PMC7815626          DOI: 10.1007/s00415-020-10144-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  47 in total

1.  Clinical features of facioscapulohumeral muscular dystrophy 2.

Authors:  J C de Greef; R J L F Lemmers; P Camaño; J W Day; S Sacconi; M Dunand; B G M van Engelen; S Kiuru-Enari; G W Padberg; A L Rosa; C Desnuelle; S Spuler; M Tarnopolsky; S L Venance; R R Frants; S M van der Maarel; R Tawil
Journal:  Neurology       Date:  2010-10-26       Impact factor: 9.910

2.  Diagnostic criteria for facioscapulohumeral muscular dystrophy.

Authors:  G W Padberg; P W Lunt; M Koch; M Fardeau
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

3.  44th ENMC International Workshop: Facioscapulohumeral Muscular Dystrophy: Molecular Studies 19-21 July 1996, Naarden, The Netherlands.

Authors:  P W Lunt
Journal:  Neuromuscul Disord       Date:  1998-04       Impact factor: 4.296

4.  225th ENMC international workshop:: A global FSHD registry framework, 18-20 November 2016, Heemskerk, The Netherlands.

Authors:  Karlien Mul; June Kinoshita; Hugh Dawkins; Baziel van Engelen; Rossella Tupler
Journal:  Neuromuscul Disord       Date:  2017-04-12       Impact factor: 4.296

5.  Population-based incidence and prevalence of facioscapulohumeral dystrophy.

Authors:  Johanna C W Deenen; Hisse Arnts; Silvère M van der Maarel; George W Padberg; Jan J G M Verschuuren; Egbert Bakker; Stephanie S Weinreich; André L M Verbeek; Baziel G M van Engelen
Journal:  Neurology       Date:  2014-08-13       Impact factor: 9.910

6.  Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample.

Authors:  M L Mostacciuolo; E Pastorello; G Vazza; M Miorin; C Angelini; G Tomelleri; G Galluzzi; C P Trevisan
Journal:  Clin Genet       Date:  2009-03-23       Impact factor: 4.438

7.  Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype.

Authors:  E Ricci; G Galluzzi; G Deidda; S Cacurri; L Colantoni; B Merico; N Piazzo; S Servidei; E Vigneti; V Pasceri; G Silvestri; M Mirabella; F Mangiola; P Tonali; L Felicetti
Journal:  Ann Neurol       Date:  1999-06       Impact factor: 10.422

8.  Phenotypic Variability Among Patients With D4Z4 Reduced Allele Facioscapulohumeral Muscular Dystrophy.

Authors:  Lucia Ruggiero; Fabiano Mele; Fiore Manganelli; Dario Bruzzese; Giulia Ricci; Liliana Vercelli; Monica Govi; Antonio Vallarola; Silvia Tripodi; Luisa Villa; Antonio Di Muzio; Marina Scarlato; Elisabetta Bucci; Giovanni Antonini; Lorenzo Maggi; Carmelo Rodolico; Giuliano Tomelleri; Massimiliano Filosto; Stefano Previtali; Corrado Angelini; Angela Berardinelli; Elena Pegoraro; Maurizio Moggio; Tiziana Mongini; Gabriele Siciliano; Lucio Santoro; Rossella Tupler
Journal:  JAMA Netw Open       Date:  2020-05-01

9.  Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy.

Authors:  Giulia Ricci; Isabella Scionti; Francesco Sera; Monica Govi; Roberto D'Amico; Ilaria Frambolli; Fabiano Mele; Massimiliano Filosto; Liliana Vercelli; Lucia Ruggiero; Angela Berardinelli; Corrado Angelini; Giovanni Antonini; Elisabetta Bucci; Michelangelo Cao; Jessica Daolio; Antonio Di Muzio; Rita Di Leo; Giuliana Galluzzi; Elisabetta Iannaccone; Lorenzo Maggi; Valerio Maruotti; Maurizio Moggio; Tiziana Mongini; Lucia Morandi; Ana Nikolic; Ebe Pastorello; Enzo Ricci; Carmelo Rodolico; Lucio Santoro; Maura Servida; Gabriele Siciliano; Giuliano Tomelleri; Rossella Tupler
Journal:  Brain       Date:  2013-09-11       Impact factor: 13.501

10.  Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry.

Authors:  Ana Nikolic; Giulia Ricci; Francesco Sera; Elisabetta Bucci; Monica Govi; Fabiano Mele; Marta Rossi; Lucia Ruggiero; Liliana Vercelli; Sabrina Ravaglia; Giacomo Brisca; Chiara Fiorillo; Luisa Villa; Lorenzo Maggi; Michelangelo Cao; Maria Chiara D'Amico; Gabriele Siciliano; Giovanni Antonini; Lucio Santoro; Tiziana Mongini; Maurizio Moggio; Lucia Morandi; Elena Pegoraro; Corrado Angelini; Antonio Di Muzio; Carmelo Rodolico; Giuliano Tomelleri; Maria Grazia D'Angelo; Claudio Bruno; Angela Berardinelli; Rossella Tupler
Journal:  BMJ Open       Date:  2016-01-05       Impact factor: 2.692

View more
  8 in total

1.  Counseling and prenatal diagnosis in facioscapulohumeral muscular dystrophy: A retrospective study on a 13-year multidisciplinary approach.

Authors:  Maria Francesca Di Feo; Cinzia Bettio; Valentina Salsi; Emma Bertucci; Rossella Tupler
Journal:  Health Sci Rep       Date:  2022-04-20

2.  Large genotype-phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis.

Authors:  Giulia Ricci; Fabiano Mele; Monica Govi; Lucia Ruggiero; Francesco Sera; Liliana Vercelli; Cinzia Bettio; Lucio Santoro; Tiziana Mongini; Luisa Villa; Maurizio Moggio; Massimiliano Filosto; Marina Scarlato; Stefano C Previtali; Silvia Maria Tripodi; Elena Pegoraro; Roberta Telese; Antonio Di Muzio; Carmelo Rodolico; Elisabetta Bucci; Giovanni Antonini; Maria Grazia D'Angelo; Angela Berardinelli; Lorenzo Maggi; Rachele Piras; Maria Antonietta Maioli; Gabriele Siciliano; Giuliano Tomelleri; Corrado Angelini; Rossella Tupler
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

Review 3.  Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.

Authors:  Teresa Schätzl; Lars Kaiser; Hans-Peter Deigner
Journal:  Orphanet J Rare Dis       Date:  2021-03-12       Impact factor: 4.123

4.  Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.

Authors:  Anita van den Heuvel; Saskia Lassche; Karlien Mul; Anna Greco; David San León Granado; Arend Heerschap; Benno Küsters; Stephen J Tapscott; Nicol C Voermans; Baziel G M van Engelen; Silvère M van der Maarel
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.379

5.  The Italian National Registry for FSHD: an enhanced data integration and an analytics framework towards Smart Health Care and Precision Medicine for a rare disease.

Authors:  Cinzia Bettio; Valentina Salsi; Mirko Orsini; Enrico Calanchi; Luca Magnotta; Luca Gagliardelli; June Kinoshita; Sonia Bergamaschi; Rossella Tupler
Journal:  Orphanet J Rare Dis       Date:  2021-11-04       Impact factor: 4.123

6.  Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy.

Authors:  Christophe Béroud; Sabrina Sacconi; Benoît Sanson; Caroline Stalens; Céline Guien; Luisa Villa; Catherine Eng; Sitraka Rabarimeriarijaona; Rafaëlle Bernard; Pascal Cintas; Guilhem Solé; Vincent Tiffreau; Andoni Echaniz-Laguna; Armelle Magot; Raul Juntas Morales; François Constant Boyer; Aleksandra Nadaj-Pakleza; Agnès Jacquin-Piques
Journal:  Orphanet J Rare Dis       Date:  2022-03-02       Impact factor: 4.123

Review 7.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

8.  Muscle Fiber Conduction Velocity Correlates With the Age at Onset in Mild FSHD Cases.

Authors:  Matteo Beretta-Piccoli; Massimo Negro; Luca Calanni; Angela Berardinelli; Gabriele Siciliano; Rossella Tupler; Emiliano Soldini; Corrado Cescon; Giuseppe D'Antona
Journal:  Front Physiol       Date:  2021-06-17       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.